Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02091999 (Clinical Trial/ ASG-22CE)

Study Title
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4. (NCT02091999)

Trial Description
The purpose of this study is to evaluate the safety and pharmacokinetics ASG-22CE  (formerly AGS-22M6E); AGS-22CE, AGS-22M, AGS-22ME, ASG-22ME, unconjugated : AGS-22C3 or AGSM6) as well as assess the immunogenicity and antitumor activity in subjects with metastatic urothelial cancer and other malignant solid tumors. This trial is sponsored by Agensys, Inc. [1]

Study Data

  • Condition: Metastatic Urothelial Cancer and Other Malignant Solid Tumors
  • Interventions:
    • Drugs used in this trial
      • ASG-22CE
  • Phase: I
  • Estimated Enrollment: 200
  • Start: June 2014
  • Estimated Completion: December 2018
  • Last verified: July 2017

Study Schematic

NCT02091999

Click here to Return to Drug map


Last Editorial review: August 25, 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar